Conference Coverage: ASCO GU 2026 Highlights
Expert perspectives and strategic insights on the latest therapeutic developments in genitourinary (GU) cancer treatment from the 2026 ASCO GU Cancers Symposium.

FACULTY CHAIR
Daniel Petrylak, MD
Yale School of Medicine, New Haven, CT, USA
Faculty Members
Robert Dreicer, MD, MACP, FASCO
University of Virginia Comprehensive Cancer Center, Charlottesville, VA, USA
David Nanus, MD
Weill Cornell Medicine, NewYork–Presbyterian Hospital, New York, NY, USA
Scott Tagawa, MD, FACP, FASCO
Weill Cornell Medicine, NewYork–Presbyterian Hospital, New York, NY, USA
Susan Slovin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Karim Fizazi, MD, PhD
Oscar Lambret Center, Lille, France
KEY TAKEWAYS
- Key Insights and Strategic Recommendations
- Prostate Cancer
- Castration-Sensitive Prostrate Cancer (CSPC)
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Renal Cell Carcinoma (RCC)
- Bladder Cancer
- Limited Stage (not including BCG)
- Advanced and Metastatic Disease
- Attendee Key Takeaways
Purchase Report
Thank you for your interest in our insights.
Complete the form below to receive additional information.